Advertisement

Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Organisation › Details

Acer Therapeutics Inc. (Nasdaq: ACER)

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms (iVMS); and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the U.S. FDA. On March 19, 2021, Acer entered into a Collaboration and License Agreement with Relief Therapeutics for worldwide development and commercialization of ACER-001. *

 

Period Start 2021-03-22 existent
Product Industry pharmaceutical
     
Region Region United States (USA)_oo
  Country United States (USA)
  City n. a. 
    Address record changed: 2021-03-29
     
Basic data Employees n. a.
     
    * Document for �About Section�: Relief Therapeutics Holding AG. (3/22/21). "Press Release: Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine D
     
   
Record changed: 2021-04-21

Advertisement

Picture Demy-Colton BioFuture 2021 NYC C Virtual Option 650x80px

More documents for Acer Therapeutics Inc. (Nasdaq: ACER)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80




» top